This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Celanese (CE) in Your Portfolio
by Zacks Equity Research
While Celanese (CE) faces challenges from demand softness and pricing pressures, it benefits from strategic acquisitions and productivity measures.
Celanese (CE) Achieves Milestones in the Acetyl Chain Business
by Zacks Equity Research
Celanese (CE) achieves milestones in cost-effective, sustainable growth, including new facilities and supply contracts, positioning for earnings increase and global expansion.
Celanese (CE) Up 39% in 6 Months: What's Driving the Rally?
by Zacks Equity Research
Celanese (CE) benefits from its productivity measures, investments in organic projects and strategic acquisitions.
Celanese (CE) Gets ISCC-Certified for Low Carbon CCU Methanol
by Zacks Equity Research
Celanese (CE) now offers low-carbon choices to customers across its Acetyl Chain and Engineered Materials products under the ECO-CC name.
Eastman Chemical (EMN) Gains on Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions, acquisitions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
Celanese (CE) and Secarna Partner for Antisense Therapies
by Zacks Equity Research
Celanese's (CE) collaboration with Secarna enables the development of a novel implant with the potential to significantly alter how disease-modifying ASO treatments are given.
Why Is Celanese (CE) Up 10% Since Last Earnings Report?
by Zacks Equity Research
Celanese (CE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Celanese (CE) Stock For Now
by Zacks Equity Research
While Celanese (CE) faces headwinds from demand softness and pricing pressures, it gains on strategic acquisitions and productivity measures.
Celanese (CE) Announces Commercial Launch of Glaukos' iDose TR
by Zacks Equity Research
iDose TR uses Celanese's (CE) VitalDose EVA. It is approved following the completion of two pivotal trials which demonstrates safety and efficacy.
Celanese's (CE) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Pricing of Celanese's (CE) Engineered Material segment declines in Q4 due to tough competition and product mix challenges in the Americas and Europe.
Celanese (CE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Celanese (CE) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
January CPI Comes in Hot But Underlying Inflation Pressures Remain Cool
by Mayur Thaker
i still expect core inflation to remain subdued which should keep a lid on yields, but cracks in consumer health and valuations remain top concerns
Celanese (CE) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Celanese (CE) delivered earnings and revenue surprises of -2.18% and 1.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
CE or BCPC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CE vs. BCPC: Which Stock Is the Better Value Option?
Celanese (CE) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Celanese (CE) is expected to have benefited from its cost actions and contributions of acquisitions amid demand headwinds in certain markets in Q4.
Earnings Preview: Mativ Holdings (MATV) Q4 Earnings Expected to Decline
by Zacks Equity Research
Mativ Holdings (MATV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Countdown to Celanese (CE) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Celanese (CE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
Celanese (CE) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Celanese (CE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Celanese (CE) Offers Low-Carbon Products Under DOE Program
by Zacks Equity Research
Celanese (CE) low carbon acetic acid product offerings have shown a significant net fall in life cycle greenhouse gas emissions and have passed a rigorous DOE examination of their life cycle analyses.
Zacks.com featured highlights Pilgrim's Pride, SkyWest, Goodyear Tire and Celanese
by Zacks Equity Research
Pilgrim's Pride, SkyWest, Goodyear Tire and Celanese have been highlighted in this Screen of The Week article.
Leverage Earnings Yield in Value Investing With These 4 Stocks
by Rimmi Singhi
By embracing value investing and leveraging the power of earnings yield, investors can uncover hidden opportunities. PPC, SKYW, GT and CE are some high-yield value stocks.
Eastman Chemical (EMN) Gains on Cost Cuts and Innovation
by Zacks Equity Research
Eastman Chemical (EMN) benefits from cost-management actions and innovation amid challenges from soft demand and consumer de-stocking in certain markets.
LyondellBasell's (LYB) Petrothene T3XL7420 to Optimize Production
by Zacks Equity Research
Petrothene T3XL7420 by LyondellBasell (LYB) passes extensive testing and certification procedures to ensure its quality and dependability.
Celanese (CE) & Under Armour Partner to Develop Sustainable Fiber
by Zacks Equity Research
Celanese (CE) and Under Armour join forces to revolutionize performance fabrics with NEOLAST, a game-changer in stretch performance and sustainability.
CE or BCPC: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CE vs. BCPC: Which Stock Is the Better Value Option?